Bruker Corporation (BRKR) Stock Analysis

Q: What is the BRKR stock price target?

Take-profit $40.70 (+13.4% upside). Prior stop was $33.36.

Q: Is BRKR overvalued or undervalued?

Bruker Corporation trades at a P/E of N/A (forward 14.2). TrendMatrix value score: 6.4/10. Overall verdict: Sell.

Q: What do analysts say about BRKR?

22 analysts cover BRKR with a consensus score of 4.0/5. Average price target: $47.

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Medical Devices

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Bruker develops and manufactures scientific instruments across four segments (BioSpin, CALID, NANO, BEST) serving life sciences, materials science, clinical microbiology, and energy sectors. Revenue was ~74% international in 2025; China contributed $475.8M, and the company faces... Read more

$35.85+13.4% A.UpsideScore 4.2/10#40 of 40 Medical Devices

Stop $33.36Target $40.70(analyst − 13%)A.R:R 1.3:1

Analyst target$46.79+30.5%14 analysts

$40.70our TP

$35.85price

$46.79mean

$60

Sell if holding. Engine safety override at $35.85: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 16%; Elevated put/call ratio: 1.75; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.2/10, moderate confidence.

Passes 4/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: moderate.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (3.6 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)14.2

Mkt Cap$5.2B

EV/EBITDA14.0

Profit Mgn-0.3%

ROE-0.4%

Rev Growth-0.2%

Beta1.20

Dividend0.58%

Rating analysts22

Quality Signals

Piotroski F6/9

Options Flow

P/C1.75bearish

IV99%elevated

Max Pain$20-44.2% vs spot

Concentration Risks(10-K Item 1A)

MEDIUMGeographicChina
10-K Item 1A: 'A significant portion of our revenue is derived from sales into China, some of which are directly funded through Chinese government stimulus programs'
MEDIUMCustomerU.S. academic and government funding
10-K Item 1A: 'A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding'

Material Events(8-K, last 90d)

2026-04-10Item 5.02MEDIUM
On April 6, 2026, Falko Busse (President of Bruker BioSpin, executive officer) agreed to transition duties ~May 2026; employment terminates October 31, 2026. Separation agreement provides ~$1M in benefits. No successor named.
SEC filing →
2026-04-01Item 5.02LOW
On March 27, 2026, Bruker expanded its Board to 12 directors and appointed Thierry L. Bernard (CEO of QIAGEN) as a Class III director effective April 1, 2026. Initial term until 2027 Annual Meeting. No reason cited.
SEC filing →
2026-02-20Item 5.02LOW
On February 16, 2026, Dr. Cynthia Friend announced she will not stand for re-election at the 2026 Annual Meeting (no disagreement cited). Jack Phillips reclassified as a Class II director for continuity.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value6.415%0.96

Quality3.615%0.54

Growth3.115%0.46

Momentum1.310%0.13

Sentiment7.110%0.71

Insider Activity5.010%0.50

Peer Rank3.010%0.30

Technical Setup5.85%0.29

Risk Profile2.85%0.14

Catalyst4.05%0.20

Overall (Σ contributions)4.23

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.0

Volume

0.1

Obv

1.0

Ma Position

1.0

Rsi

4.5

Volume distribution (falling OBV)Below 200-MA, MA slope -1.2%/30d — confirmed downtrend

Volatile — 5.2% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility

0.0

Implied Vol

0.0

Put Call

1.7

Short Interest

1.9

Max Pain Risk

3.0

Days To Cover

3.7

Debt Equity

6.1

Beta

6.2

High short interest justified: 16%Elevated put/call: 1.75High IV: 99%Above max pain $20Concentration risks: 2 MED (10-K Item 1A)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

0.8

Quality Rank

3.6

Value Rank

7.8

Revenue shrinking — -0.2% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth

2.5

Earnings Growth

3.7

Declining revenue: -0%

Unprofitable operations — net margin -0.3%. Quality floor flags this regardless of sector context.static

Roe

0.0

Net Margin

0.0

Roa

1.9

Operating Margin

2.6

Fcf Quality

4.8

Moat

5.0

Gross Margin

5.6

Current Ratio

6.2

Piotroski F

6.7

FCF-positive but moderate margins (FCF margin 6%, FCF yield 4.2%)No competitive moat

GatesMomentum 1.3<4.5A.R:R 1.3 < 1.5@spotDeath cross (50MA < 200MA)EARNINGS PROXIMITY 6d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Moderate

RSI

44 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $33.80Resistance $42.64

Price Targets

$33

$41

A.Upside+13.5%

A.R:R1.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.6 < 4.0)

! Momentum score 1.3/10 — below 4.5 minimum

! Reward/Risk 1.3:1 at current price — below 1.5:1 minimum

Earnings

1/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is BRKR stock a buy right now?

Sell if holding. Engine safety override at $35.85: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 16%; Elevated put/call ratio: 1.75; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $33.36. Score 4.2/10, moderate confidence.

What is the BRKR stock price target?

Take-profit target: $40.70 (+13.4% upside). Prior stop was $33.36. Stop-loss: $33.36.

What are the risks of investing in BRKR?

Quality below floor (3.6 < 4.0).

Is BRKR overvalued or undervalued?

Bruker Corporation trades at a P/E of N/A (forward 14.2). TrendMatrix value score: 6.4/10. Verdict: Sell.

What do analysts say about BRKR?

22 analysts cover BRKR with a consensus score of 4.0/5. Average price target: $47.

What does Bruker Corporation do?Bruker develops and manufactures scientific instruments across four segments (BioSpin, CALID, NANO, BEST) serving life...